Investors

Breath Therapeutics is financed by top-tier investors Sofinnova Partners, Gimv, and Gilde Healthcare.

With a USD 46 million Series A round of financing we are in the position to complete the Phase 3 studies of our lead program BOSTON in Bronchiolitis Obliterans.